<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00056160</url>
  </required_header>
  <id_info>
    <org_study_id>CC-5013-MM-009</org_study_id>
    <nct_id>NCT00056160</nct_id>
  </id_info>
  <brief_title>CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma</brief_title>
  <official_title>A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing
      identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will
      participate in a treatment phase and a follow-up phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a phase 3, multicenter, double-blind, placebo-controlled, parallel-group study of
      the efficacy and safety of CC-5013 plus oral pulse high-dose dexamethasone and oral pulse
      high-dose dexamethasone therapy alone in subjects with relapsed or refractory multiple
      myeloma. Eligible subjects were randomized in a 1:1 ratio to 1 of 2 treatment groups:
      Subjects in the CC-5013/Dex treatment group took 25 mg of CC-5013 orally once daily on Days 1
      to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle;
      Subjects in the Placebo/Dex treatment group took 1 placebo capsule on Days 1 to 28 of each
      28-day cycle. Subjects in both treatment groups took 40 mg of dexamethasone orally once daily
      on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy.
      Beginning with Cycle 5, the dose of dexamethasone was reduced to 40 mg orally once daily on
      Days 1 to 4 for the remaining cycles.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2003</start_date>
  <completion_date type="Actual">October 1, 2008</completion_date>
  <primary_completion_date type="Actual">November 1, 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Tumor Progression (TTP)</measure>
    <time_frame>60 weeks (median Time To Progression of CC-5013/Dex treatment group)</time_frame>
    <description>Time to progression (TTP) was calculated as the time from randomization to the first documentation of progressive disease based on the myeloma response determination criteria developed by Bladé et. al., Br J Haematol 1998; 102:1115-1123.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>170 weeks (median overall survival of CC-5013/Dex treatment group)</time_frame>
    <description>Overall survival was calculated as the time from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myeloma Response</measure>
    <time_frame>Up to Unblinding (07 Jun 2005)</time_frame>
    <description>The overall confirmed response that was maintained for ≥6 weeks. Complete Response (CR):Disappearance of monoclonal paraprotein. Remission Response (RR):75-99% reduction in monoclonal paraprotein/90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR):50-74% reduction in monoclonal paraprotein/50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD):Criteria for PR or PD not met. Plateau Phase:If PR, stable monoclonal paraprotein (within 25% above or below nadir)/stable soft tissue plasmacytomas. Progressive Disease (PD):Disease worsens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Worsening of Eastern Cooperative Oncology Group (ECOG) Performance Status Scale (Best Score=0, Fully Active, Able to Carry on All Pre-disease Performance Without Restriction; Worst Score=5, Dead.)</measure>
    <time_frame>30 weeks (mean time to first worsening of ECOG performance status for CC-5013/Dex treatment group)</time_frame>
    <description>The time to first worsening on the ECOG Performance Scale was calculated as the time from randomization to the date of the first worsening compared to the last ECOG evaluation obtained prior to randomization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">353</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>CC-5013/Dex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-5013 (lenalidomide) plus oral high-dose dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Dex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-5013</intervention_name>
    <description>Subjects in the CC-5013/Dex treatment group took 25 mg of lenalidomide orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle.</description>
    <arm_group_label>CC-5013/Dex</arm_group_label>
    <other_name>lenalidomide</other_name>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Subjects in the CC-5013/Dex and Placebo/Dex treatment groups took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. Beginning with Cycle 5, the dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 for the remaining cycles.</description>
    <arm_group_label>CC-5013/Dex</arm_group_label>
    <arm_group_label>Placebo/Dex</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior or current diagnosis Durie-Salmon stage II or III multiple myeloma.

          -  No more than 3 previous anti-myeloma regimens

          -  No high-dose dexamethasone (total monthly dose of dexamethasone greater than 200 mg)
             within 6 months of study randomization.

          -  Measurable levels of myeloma paraprotein in serum or urine (24-hour collection
             sample).

        Exclusion Criteria:

          -  Prior development of disease progression during high-dose dexamethasone containing
             therapy.

          -  Laboratory abnormalities: Absolute neutrophil count less than 1,000 cells/mm cubed

          -  Laboratory abnormalities: Platelet count less than 75,000/mm cubed

          -  Laboratory abnormalities: Serum creatinine greater than 2.5 mg/dL

          -  Laboratory abnormalities: Serum glutamic oxaloacetic transaminase (SGOT, aspartate
             transaminase [AST]) or serum glutamic pyruvic transaminase (SGPT, alanine transaminase
             [ALT])greater than 3.0 x upper limit of normal

          -  Laboratory abnormalities: Serum total bilirubin greater than 2.0 mg/dL

          -  Prior history of malignancies other than multiple myeloma unless the subject has been
             free of the disease for greater than or equal to 5 years.

          -  Known hypersensitivity to thalidomide or dexamethasone.

          -  Development of a desquamating rash while taking thalidomide.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Knight, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Consultants, Inc.</name>
      <address>
        <city>Hoover</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF California</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center, Division of Hematology</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic- Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Consultants</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Georgia</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912-3125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Med Ctr</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2927</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Cancer Institute Section of Hematology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-3824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Cancer Research Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospital Clinic</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocshner Clinical Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Medicine Department of Oncology</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine- Sherman Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP Our Lady of Mercy Cancer Center New York Medical College</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Myeloma Program</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Northwest Region Center for Health Research</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Hematology/Oncology P.A.</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of SC</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Carolina Oncology Group</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203-1632</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital/BMT Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3522</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dalhousie University</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5J2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Charles LeMoyne</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>PQH2W1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/clinical-study-report-csr-synopses/purposes-of-posting-clinical-study-report-csr-synopses</url>
    <description>Link to CSR synopsis</description>
  </link>
  <results_reference>
    <citation>Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007 Nov 22;357(21):2133-42.</citation>
    <PMID>18032763</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2003</study_first_submitted>
  <study_first_submitted_qc>March 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2003</study_first_posted>
  <results_first_submitted>December 24, 2009</results_first_submitted>
  <results_first_submitted_qc>February 2, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 3, 2010</results_first_posted>
  <last_update_submitted>September 18, 2017</last_update_submitted>
  <last_update_submitted_qc>September 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Refractory and Relapsed</keyword>
  <keyword>Revlimid</keyword>
  <keyword>CC5013</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects in the Placebo/Dex treatment group did not continue participation beyond the period &quot;Up To Unblinding (07 Jun 2005&quot;). Only subjects in the CC-5013/Dex treatment group participated in the period &quot;Extended Follow-up Cutoff (23 Jul 2008)&quot;.</recruitment_details>
      <pre_assignment_details>Only subjects in the CC-5013/Dex treatment group participated in the period &quot;Extended Follow-up Cutoff (23 Jul 2008)&quot;. Data for the period &quot;Extended Follow-up Cutoff (23 Jul 2008)&quot; subsumes data for the period &quot;Up To Unblinding (07 Jun 2005)&quot;.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CC-5013/Dex</title>
          <description>CC-5013 (lenalidomide) plus oral high-dose dexamethasone</description>
        </group>
        <group group_id="P2">
          <title>Placebo/Dex</title>
          <description>Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Up to Unblinding (07 Jun 2005)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="177"/>
                <participants group_id="P2" count="176"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="163"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progression of disease</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="124"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extended Follow-up Cutoff (23 Jul 2008)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="177"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progression of disease</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Final Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Transferred into expanded access study.</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transferred into RevAssist Program</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CC-5013/Dex</title>
          <description>CC-5013 (lenalidomide) plus oral high-dose dexamethasone</description>
        </group>
        <group group_id="B2">
          <title>Placebo/Dex</title>
          <description>Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="177"/>
            <count group_id="B2" value="176"/>
            <count group_id="B3" value="353"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="197"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.3" spread="9.84"/>
                    <measurement group_id="B2" value="62.5" spread="9.81"/>
                    <measurement group_id="B3" value="62.9" spread="9.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Tumor Progression (TTP)</title>
        <description>Time to progression (TTP) was calculated as the time from randomization to the first documentation of progressive disease based on the myeloma response determination criteria developed by Bladé et. al., Br J Haematol 1998; 102:1115-1123.</description>
        <time_frame>60 weeks (median Time To Progression of CC-5013/Dex treatment group)</time_frame>
        <population>Analysis conducted on the Intent-To-Treat (ITT) Population. The ITT Population was defined as all subjects randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>CC-5013/Dex</title>
            <description>CC-5013 (lenalidomide) plus oral high-dose dexamethasone</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Dex</title>
            <description>Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Tumor Progression (TTP)</title>
          <description>Time to progression (TTP) was calculated as the time from randomization to the first documentation of progressive disease based on the myeloma response determination criteria developed by Bladé et. al., Br J Haematol 1998; 102:1115-1123.</description>
          <population>Analysis conducted on the Intent-To-Treat (ITT) Population. The ITT Population was defined as all subjects randomized.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.1" lower_limit="41.1" upper_limit="80.0"/>
                    <measurement group_id="O2" value="20.1" lower_limit="16.1" upper_limit="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival was calculated as the time from randomization to death from any cause.</description>
        <time_frame>170 weeks (median overall survival of CC-5013/Dex treatment group)</time_frame>
        <population>Analysis conducted on the Intent-To-Treat (ITT) Population. The ITT Population was defined as all subjects randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>CC-5013/Dex</title>
            <description>CC-5013 (lenalidomide) plus oral high-dose dexamethasone</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Dex</title>
            <description>Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival was calculated as the time from randomization to death from any cause.</description>
          <population>Analysis conducted on the Intent-To-Treat (ITT) Population. The ITT Population was defined as all subjects randomized.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170.1" lower_limit="142.1" upper_limit="204.9"/>
                    <measurement group_id="O2" value="136.4" lower_limit="104.1" upper_limit="176.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myeloma Response</title>
        <description>The overall confirmed response that was maintained for ≥6 weeks. Complete Response (CR):Disappearance of monoclonal paraprotein. Remission Response (RR):75-99% reduction in monoclonal paraprotein/90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR):50-74% reduction in monoclonal paraprotein/50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD):Criteria for PR or PD not met. Plateau Phase:If PR, stable monoclonal paraprotein (within 25% above or below nadir)/stable soft tissue plasmacytomas. Progressive Disease (PD):Disease worsens.</description>
        <time_frame>Up to Unblinding (07 Jun 2005)</time_frame>
        <population>Analysis conducted on the Intent-To-Treat (ITT) Population. The ITT Population was defined as all subjects randomized. Results reported (Response) are numbers of subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>CC-5013/Dex</title>
            <description>CC-5013 (lenalidomide) plus oral high-dose dexamethasone</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Dex</title>
            <description>Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone</description>
          </group>
        </group_list>
        <measure>
          <title>Myeloma Response</title>
          <description>The overall confirmed response that was maintained for ≥6 weeks. Complete Response (CR):Disappearance of monoclonal paraprotein. Remission Response (RR):75-99% reduction in monoclonal paraprotein/90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR):50-74% reduction in monoclonal paraprotein/50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD):Criteria for PR or PD not met. Plateau Phase:If PR, stable monoclonal paraprotein (within 25% above or below nadir)/stable soft tissue plasmacytomas. Progressive Disease (PD):Disease worsens.</description>
          <population>Analysis conducted on the Intent-To-Treat (ITT) Population. The ITT Population was defined as all subjects randomized. Results reported (Response) are numbers of subjects.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Worsening of Eastern Cooperative Oncology Group (ECOG) Performance Status Scale (Best Score=0, Fully Active, Able to Carry on All Pre-disease Performance Without Restriction; Worst Score=5, Dead.)</title>
        <description>The time to first worsening on the ECOG Performance Scale was calculated as the time from randomization to the date of the first worsening compared to the last ECOG evaluation obtained prior to randomization.</description>
        <time_frame>30 weeks (mean time to first worsening of ECOG performance status for CC-5013/Dex treatment group)</time_frame>
        <population>Analysis conducted on the Intent-To-Treat (ITT) Population. The ITT Population was defined as all subjects randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>CC-5013/Dex</title>
            <description>CC-5013 (lenalidomide) plus oral high-dose dexamethasone</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Dex</title>
            <description>Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Worsening of Eastern Cooperative Oncology Group (ECOG) Performance Status Scale (Best Score=0, Fully Active, Able to Carry on All Pre-disease Performance Without Restriction; Worst Score=5, Dead.)</title>
          <description>The time to first worsening on the ECOG Performance Scale was calculated as the time from randomization to the date of the first worsening compared to the last ECOG evaluation obtained prior to randomization.</description>
          <population>Analysis conducted on the Intent-To-Treat (ITT) Population. The ITT Population was defined as all subjects randomized.</population>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" spread="30.02"/>
                    <measurement group_id="O2" value="15.0" spread="16.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 254 weeks (median=48 weeks; mean=77 weeks)</time_frame>
      <desc>Analyses of safety (Serious Adverse Events and Other Adverse Events) were based upon the Safety Population (all subjects who were administered at least one dose of study medication) and include all data available.</desc>
      <group_list>
        <group group_id="E1">
          <title>CC-5013/Dex</title>
          <description>CC-5013 (lenalidomide) plus oral high-dose dexamethasone</description>
        </group>
        <group group_id="E2">
          <title>Placebo/Dex</title>
          <description>Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (5.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPERVISCOSITY SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="177"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ARTERIOSPASM CORONARY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SINUS TACHYCARDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>ADRENAL INSUFFICIENCY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>BLINDNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BLINDNESS TRANSIENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CATARACT UNILATERAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>RETINAL VEIN OCCLUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>COLITIS PSEUDOMEMBRANOUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DIVERTICULAR PERFORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>GINGIVAL BLEEDING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>INTESTINAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>LOWER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CATHETER SITE PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="177"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SYSTEMIC INFLAMMATORY RESPONSE SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HEPATITIS TOXIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABSCESS INTESTINAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ANAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>APPENDICEAL ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ARTHRITIS BACTERIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CATHETER RELATED INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CELLULITIS STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM COLITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ENCEPHALITIS HERPES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ENTEROBACTER BACTERAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HERPES VIRAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PNEUMOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PNEUMOCYSTIS CARINII PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PNEUMONIA BACTERIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PNEUMONIA CYTOMEGALOVIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PNEUMONIA FUNGAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="39" subjects_affected="30" subjects_at_risk="177"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PNEUMONIA PRIMARY ATYPICAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PNEUMONIA STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PNEUMONIA STREPTOCOCCAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="177"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SINUSITIS FUNGAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>STREPTOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>STREPTOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SUBACUTE ENDOCARDITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>TOOTH ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACETABULUM FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>FIBULA FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MULTIPLE FRACTURES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>VASCULAR GRAFT OCCLUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD BILIRUBIN ABNORMAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>INTERNATIONAL NORMALISED RATIO INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TESTS ABNORMAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="177"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DIABETES WITH HYPEROSMOLARITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>FLUID OVERLOAD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPERAMMONAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPERCALCAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPOALBUMINAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>METABOLIC ACIDOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CHEST WALL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MUSCLE WEAKNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MYOPATHY STEROID</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BRONCHIOLOALVEOLAR CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>LEUKAEMIA PLASMACYTIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>LUNG NODULE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>METASTASES TO LIVER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MYELODYSPLASTIC SYNDROME</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PLASMACYTOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF SKIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBELLAR INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CONVULSIONS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DEPRESSED LEVEL OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL VENOUS SINUS THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>LEUKOENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SPINAL CORD COMPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DELUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MAJOR DEPRESSIVE DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PSYCHOTIC DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>AZOTAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>FANCONI SYNDROME ACQUIRED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="177"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="177"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>RENAL TUBULAR NECROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACQUIRED BRONCHOMALACIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE AIRWAYS DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXACERBATED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>EMPHYSEMATOUS BULLA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" events="24" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SKIN DESQUAMATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SKIN DISCOLOURATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ARTERIAL THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="177"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SUPERIOR VENA CAVAL OCCLUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (5.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="139" subjects_affected="72" subjects_at_risk="177"/>
                <counts group_id="E2" events="44" subjects_affected="37" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="177"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="348" subjects_affected="87" subjects_at_risk="177"/>
                <counts group_id="E2" events="22" subjects_affected="12" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="83" subjects_affected="45" subjects_at_risk="177"/>
                <counts group_id="E2" events="28" subjects_affected="19" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>CUSHINGOID</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="177"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CATARACT UNILATERAL</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="177"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" events="79" subjects_affected="50" subjects_at_risk="177"/>
                <counts group_id="E2" events="56" subjects_affected="30" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="177"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="27" subjects_affected="20" subjects_at_risk="177"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="177"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="99" subjects_affected="74" subjects_at_risk="177"/>
                <counts group_id="E2" events="43" subjects_affected="35" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="174" subjects_affected="85" subjects_at_risk="177"/>
                <counts group_id="E2" events="85" subjects_affected="53" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="177"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="41" subjects_affected="37" subjects_at_risk="177"/>
                <counts group_id="E2" events="37" subjects_affected="28" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="177"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="177"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>LOOSE STOOLS</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="177"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="90" subjects_affected="58" subjects_at_risk="177"/>
                <counts group_id="E2" events="79" subjects_affected="55" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ORAL PAIN</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" events="23" subjects_affected="15" subjects_at_risk="177"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="177"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="32" subjects_affected="26" subjects_at_risk="177"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="59" subjects_affected="43" subjects_at_risk="177"/>
                <counts group_id="E2" events="66" subjects_affected="47" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="34" subjects_affected="22" subjects_at_risk="177"/>
                <counts group_id="E2" events="24" subjects_affected="15" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="191" subjects_affected="114" subjects_at_risk="177"/>
                <counts group_id="E2" events="164" subjects_affected="105" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="177"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="177"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>OEDEMA</sub_title>
                <counts group_id="E1" events="22" subjects_affected="15" subjects_at_risk="177"/>
                <counts group_id="E2" events="22" subjects_affected="18" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="87" subjects_affected="58" subjects_at_risk="177"/>
                <counts group_id="E2" events="54" subjects_affected="42" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="177"/>
                <counts group_id="E2" events="25" subjects_affected="19" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="85" subjects_affected="54" subjects_at_risk="177"/>
                <counts group_id="E2" events="48" subjects_affected="35" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>RIGORS</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="177"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="177"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HERPES SIMPLEX</sub_title>
                <counts group_id="E1" events="22" subjects_affected="15" subjects_at_risk="177"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="177"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="31" subjects_affected="23" subjects_at_risk="177"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="41" subjects_affected="26" subjects_at_risk="177"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="31" subjects_affected="18" subjects_at_risk="177"/>
                <counts group_id="E2" events="13" subjects_affected="7" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="177"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TESTS ABNORMAL</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="177"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="177"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="39" subjects_affected="35" subjects_at_risk="177"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>APPETITE DECREASED</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="177"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="26" subjects_affected="21" subjects_at_risk="177"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>FLUID RETENTION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="177"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" events="62" subjects_affected="37" subjects_at_risk="177"/>
                <counts group_id="E2" events="28" subjects_affected="24" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="177"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="177"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="91" subjects_affected="34" subjects_at_risk="177"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" events="34" subjects_affected="21" subjects_at_risk="177"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPOPHOSPHATAEMIA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="177"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="63" subjects_affected="41" subjects_at_risk="177"/>
                <counts group_id="E2" events="51" subjects_affected="35" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="71" subjects_affected="57" subjects_at_risk="177"/>
                <counts group_id="E2" events="40" subjects_affected="38" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" events="31" subjects_affected="20" subjects_at_risk="177"/>
                <counts group_id="E2" events="25" subjects_affected="15" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CHEST WALL PAIN</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="177"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>JOINT SWELLING</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="177"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MUSCLE CRAMP</sub_title>
                <counts group_id="E1" events="120" subjects_affected="69" subjects_at_risk="177"/>
                <counts group_id="E2" events="61" subjects_affected="41" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="177"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MUSCLE WEAKNESS</sub_title>
                <counts group_id="E1" events="37" subjects_affected="27" subjects_at_risk="177"/>
                <counts group_id="E2" events="31" subjects_affected="29" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL STIFFNESS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="177"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="177"/>
                <counts group_id="E2" events="26" subjects_affected="22" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PAIN IN LIMB</sub_title>
                <counts group_id="E1" events="38" subjects_affected="28" subjects_at_risk="177"/>
                <counts group_id="E2" events="23" subjects_affected="13" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SWELLING</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="177"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>AGEUSIA</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="177"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BALANCE IMPAIRED</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="177"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="102" subjects_affected="51" subjects_at_risk="177"/>
                <counts group_id="E2" events="54" subjects_affected="43" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" events="37" subjects_affected="34" subjects_at_risk="177"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="79" subjects_affected="56" subjects_at_risk="177"/>
                <counts group_id="E2" events="66" subjects_affected="54" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="177"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>NEUROPATHY</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="177"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" events="31" subjects_affected="24" subjects_at_risk="177"/>
                <counts group_id="E2" events="23" subjects_affected="18" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PERIPHERAL NEUROPATHY</sub_title>
                <counts group_id="E1" events="33" subjects_affected="27" subjects_at_risk="177"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="177"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" events="44" subjects_affected="36" subjects_at_risk="177"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="38" subjects_affected="32" subjects_at_risk="177"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="177"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="31" subjects_affected="29" subjects_at_risk="177"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="99" subjects_affected="84" subjects_at_risk="177"/>
                <counts group_id="E2" events="84" subjects_affected="70" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="177"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MOOD ALTERATION</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="177"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MOOD SWINGS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="177"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>NOCTURIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="177"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>URINARY FREQUENCY</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="177"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="24" subjects_affected="19" subjects_at_risk="177"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="91" subjects_affected="53" subjects_at_risk="177"/>
                <counts group_id="E2" events="53" subjects_affected="48" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="177"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="64" subjects_affected="51" subjects_at_risk="177"/>
                <counts group_id="E2" events="47" subjects_affected="39" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="177"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HICCUPS</sub_title>
                <counts group_id="E1" events="26" subjects_affected="11" subjects_at_risk="177"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HOARSENESS</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="177"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="177"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="82" subjects_affected="39" subjects_at_risk="177"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" events="55" subjects_affected="33" subjects_at_risk="177"/>
                <counts group_id="E2" events="22" subjects_affected="18" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PRODUCTIVE COUGH</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="177"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="177"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="123" subjects_affected="63" subjects_at_risk="177"/>
                <counts group_id="E2" events="59" subjects_affected="39" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="177"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="24" subjects_affected="19" subjects_at_risk="177"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ECCHYMOSIS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="177"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="177"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>FACE OEDEMA</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="177"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>NIGHT SWEATS</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="177"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="30" subjects_affected="20" subjects_at_risk="177"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="83" subjects_affected="55" subjects_at_risk="177"/>
                <counts group_id="E2" events="30" subjects_affected="28" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SWEATING INCREASED</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="177"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>FLUSHING</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="177"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="177"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator shall have the right to publish and/or present the clinical data generated from the study provided that such Investigator shall furnish sponsor with a copy of the proposed publication or presentation at least 60 days in advance of submission, delete any confidential information, and delay submission for up to 90 days to permit the preparation and filing of appropriate intellectual property applications.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Analyses for efficacy had data cutoff dates of 07 Jun 2005 and a data cutoff date of 23 Jul 2008 for overall survival. Only safety data were collected for 6 subjects ongoing beyond the 23 Jul 2008 data cutoff date.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert Knight, M.D.</name_or_title>
      <organization>Celgene Corporation</organization>
      <phone>908-673-9749</phone>
      <email>rknight@celgene.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

